TELESIS BIO INC (TBIO) Fundamental Analysis & Valuation

NASDAQ:TBIO • US1920032000

Current stock price

3.23 USD
-0.76 (-19.05%)
At close:
2.85 USD
-0.38 (-11.76%)
After Hours:

This TBIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TBIO Profitability Analysis

1.1 Basic Checks

  • In the past year TBIO has reported negative net income.
  • TBIO had a negative operating cash flow in the past year.
  • In the past 5 years TBIO always reported negative net income.
  • TBIO had a negative operating cash flow in each of the past 5 years.
TBIO Yearly Net Income VS EBIT VS OCF VS FCFTBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

  • With a Return On Assets value of -98.37%, TBIO is not doing good in the industry: 92.98% of the companies in the same industry are doing better.
  • TBIO has a Return On Equity of -521.49%. This is amonst the worse of the industry: TBIO underperforms 91.23% of its industry peers.
Industry RankSector Rank
ROA -98.37%
ROE -521.49%
ROIC N/A
ROA(3y)-54.24%
ROA(5y)-50.23%
ROE(3y)-104.32%
ROE(5y)-94.65%
ROIC(3y)N/A
ROIC(5y)N/A
TBIO Yearly ROA, ROE, ROICTBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

  • TBIO has a Gross Margin of 47.88%. This is comparable to the rest of the industry: TBIO outperforms 54.39% of its industry peers.
  • TBIO's Gross Margin has improved in the last couple of years.
  • TBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.78%
GM growth 5YN/A
TBIO Yearly Profit, Operating, Gross MarginsTBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. TBIO Health Analysis

2.1 Basic Checks

  • TBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TBIO has more shares outstanding than it did 1 year ago.
  • TBIO has a better debt/assets ratio than last year.
TBIO Yearly Shares OutstandingTBIO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 500K 1M 1.5M
TBIO Yearly Total Debt VS Total AssetsTBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

  • TBIO has an Altman-Z score of -6.48. This is a bad value and indicates that TBIO is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -6.48, TBIO is not doing good in the industry: 91.23% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 0.54 indicates that TBIO is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.54, TBIO is not doing good in the industry: 63.16% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF N/A
Altman-Z -6.48
ROIC/WACCN/A
WACC14.42%
TBIO Yearly LT Debt VS Equity VS FCFTBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

  • TBIO has a Current Ratio of 1.89. This is a normal value and indicates that TBIO is financially healthy and should not expect problems in meeting its short term obligations.
  • TBIO has a worse Current ratio (1.89) than 61.40% of its industry peers.
  • A Quick Ratio of 1.72 indicates that TBIO should not have too much problems paying its short term obligations.
  • TBIO's Quick ratio of 1.72 is in line compared to the rest of the industry. TBIO outperforms 45.61% of its industry peers.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.72
TBIO Yearly Current Assets VS Current LiabilitesTBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. TBIO Growth Analysis

3.1 Past

  • The earnings per share for TBIO have decreased strongly by -1673.33% in the last year.
  • Looking at the last year, TBIO shows a very negative growth in Revenue. The Revenue has decreased by -43.65% in the last year.
  • The Revenue has been growing by 61.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1673.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2621.43%
Revenue 1Y (TTM)-43.65%
Revenue growth 3Y61.13%
Revenue growth 5YN/A
Sales Q2Q%-82.09%

3.2 Future

  • The Earnings Per Share is expected to decrease by -29.72% on average over the next years. This is quite bad
  • Based on estimates for the next years, TBIO will show a very negative growth in Revenue. The Revenue will decrease by -40.92% on average per year.
EPS Next Y-122.26%
EPS Next 2Y-29.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-66.55%
Revenue Next 2Y-40.92%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TBIO Yearly Revenue VS EstimatesTBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
TBIO Yearly EPS VS EstimatesTBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

0

4. TBIO Valuation Analysis

4.1 Price/Earnings Ratio

  • TBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year TBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TBIO Price Earnings VS Forward Price EarningsTBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TBIO Per share dataTBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

  • TBIO's earnings are expected to decrease with -29.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.72%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TBIO Dividend Analysis

5.1 Amount

  • TBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

TBIO Fundamentals: All Metrics, Ratios and Statistics

TELESIS BIO INC

NASDAQ:TBIO (9/27/2024, 8:22:41 PM)

After market: 2.85 -0.38 (-11.76%)

3.23

-0.76 (-19.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Industry Strength21.12
Industry Growth54.04
Earnings (Last)08-07
Earnings (Next)11-11
Inst Owners2.63%
Inst Owner Change0%
Ins Owners5195.21%
Ins Owner Change0%
Market Cap5.72M
Revenue(TTM)17.53M
Net Income(TTM)-51.87M
Analysts82.86
Price Target4.08 (26.32%)
Short Float %0.01%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-58.05%
Min EPS beat(2)-85.37%
Max EPS beat(2)-30.72%
EPS beat(4)0
Avg EPS beat(4)-35.22%
Min EPS beat(4)-85.37%
Max EPS beat(4)-2.5%
EPS beat(8)4
Avg EPS beat(8)-9.5%
EPS beat(12)5
Avg EPS beat(12)-9.14%
EPS beat(16)8
Avg EPS beat(16)19.54%
Revenue beat(2)0
Avg Revenue beat(2)-63.87%
Min Revenue beat(2)-76.62%
Max Revenue beat(2)-51.12%
Revenue beat(4)0
Avg Revenue beat(4)-39.08%
Min Revenue beat(4)-76.62%
Max Revenue beat(4)-2.28%
Revenue beat(8)2
Avg Revenue beat(8)-15.2%
Revenue beat(12)4
Avg Revenue beat(12)-9.56%
Revenue beat(16)5
Avg Revenue beat(16)-24.1%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-101.22%
EPS NY rev (1m)0%
EPS NY rev (3m)-64.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-74.68%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-65.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.33
P/FCF N/A
P/OCF N/A
P/B 0.57
P/tB 1
EV/EBITDA N/A
EPS(TTM)-23.94
EYN/A
EPS(NY)-19.27
Fwd EYN/A
FCF(TTM)-12.84
FCFYN/A
OCF(TTM)-12.31
OCFYN/A
SpS9.9
BVpS5.62
TBVpS3.22
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -98.37%
ROE -521.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.88%
FCFM N/A
ROA(3y)-54.24%
ROA(5y)-50.23%
ROE(3y)-104.32%
ROE(5y)-94.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.78%
GM growth 5YN/A
F-Score4
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.13%
Cap/Sales 5.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.72
Altman-Z -6.48
F-Score4
WACC14.42%
ROIC/WACCN/A
Cap/Depr(3y)185.64%
Cap/Depr(5y)117.94%
Cap/Sales(3y)13.42%
Cap/Sales(5y)9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1673.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2621.43%
EPS Next Y-122.26%
EPS Next 2Y-29.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-43.65%
Revenue growth 3Y61.13%
Revenue growth 5YN/A
Sales Q2Q%-82.09%
Revenue Next Year-66.55%
Revenue Next 2Y-40.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.86%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.42%
OCF growth 3YN/A
OCF growth 5YN/A

TELESIS BIO INC / TBIO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for TELESIS BIO INC?

ChartMill assigns a fundamental rating of 1 / 10 to TBIO.


What is the valuation status of TELESIS BIO INC (TBIO) stock?

ChartMill assigns a valuation rating of 0 / 10 to TELESIS BIO INC (TBIO). This can be considered as Overvalued.


What is the profitability of TBIO stock?

TELESIS BIO INC (TBIO) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for TBIO stock?

The Earnings per Share (EPS) of TELESIS BIO INC (TBIO) is expected to decline by -122.26% in the next year.